This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

ZTlido

SCILEX Pharmaceuticals, Inc.

Drug Names(s): lidocaine patch 1.8%

Description: ZTlido (lidocaine patch 1.8%), is a next-generation branded lidocaine patch formulation.

Deal Structure: Scintilla and Scilex
In August 2016, Scintilla Pharmaceuticals, a subsidiary of Sorrento Therapeutics, has entered into a binding term sheet to acquire SCILEX Pharmaceuticals. The acquisition is contingent upon completion of each parties' due diligence and other customary closing conditions. In consideration for the acquisition, SCILEX equity holders will receive up to $70 million in stock of Scintilla, following the next equity financing of Scintilla.


ZTlido News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug